Buy Glutathione 600mg

Glutathione (γ-L-glutamyl-L-cysteinyl-glycine, GSH) is the most abundant intracellular antioxidant in mammals, present at millimolar concentrations in most cell types and synthesised de novo in virtually every nucleated cell. Its three-amino-acid structure belies extraordinary biochemical versatility: the free thiol group of the central cysteine residue is the reactive centre that underpins its antioxidant, detoxification, and signalling functions. GSH neutralises reactive oxygen species (ROS) including hydrogen peroxide, hydroxyl radicals, and peroxynitrite by direct reaction, becoming oxidised to glutathione disulphide (GSSG) in the process. The ratio of GSH to GSSG within a cell is a sensitive indicator of cellular redox state and a key regulator of redox-sensitive signalling pathways. The enzymatic systems coupled to glutathione extend its antioxidant capacity far beyond simple radical scavenging. Glutathione peroxidases (GPx1-8) use GSH as a cofactor to reduce lipid hydroperoxides and H₂O₂, protecting membrane integrity and preventing lipid peroxidation cascades that damage cellular membranes and organelles. Glutathione S-transferases (GSTs) conjugate GSH to electrophilic xenobiotics, heavy metals, and endogenous toxic metabolites, enabling their export from the cell via multidrug resistance-associated proteins (MRPs). This detoxification role positions glutathione as a central node in cellular protection against both exogenous chemical toxicants and endogenous metabolic byproducts. When GSH depletion occurs — through excessive oxidative load, toxin exposure, or inadequate synthesis capacity — cells become progressively more vulnerable to oxidative damage, apoptosis, and necrosis. Glutathione's role in immune function is mechanistically distinct from its antioxidant activity. Lymphocyte proliferation, natural killer (NK) cell cytotoxicity, and antigen-presenting cell function are all GSH-dependent processes. T cell activation and the Th1/Th2 cytokine balance are regulated in part by intracellular redox state: depleted GSH shifts immune responses toward Th2 predominance (allergic/atopic) and impairs the oxidative burst of neutrophils required for pathogen killing. This immune-modulatory dimension of glutathione is a major reason for research interest in GSH supplementation in contexts of infection, chronic inflammation, and immune senescence. The mitochondrial glutathione pool (mGSH) deserves separate attention as it is mechanistically critical in tissue healing. Mitochondria generate ATP through oxidative phosphorylation, producing ROS as an unavoidable byproduct. mGSH is the primary defence against mitochondrial oxidative damage and is essential for maintaining mitochondrial membrane potential, cytochrome c retention, and the prevention of the mitochondrial permeability transition — a catastrophic event that releases pro-apoptotic factors into the cytosol. In ischaemia-reperfusion injury (a key mechanism of damage in acute injuries, surgical procedures, and cardiac events), the burst of ROS generated upon reperfusion depletes mGSH rapidly. Exogenous glutathione supplementation that reaches the mitochondrial pool can substantially limit reperfusion injury — a finding with direct relevance to surgical recovery research.

Glutathione at 600mg is appropriate for researchers investigating oxidative stress biology, ischaemia-reperfusion injury, post-surgical recovery, immune function, liver protection, neurodegenerative disease models, or skin pigmentation mechanisms. The 600mg dose per vial corresponds to the range most commonly studied in IV glutathione clinical trials, making it directly applicable to translational research designs. Researchers using oral or subcutaneous routes should be aware that bioavailability differs substantially between routes, and dose selection should reflect the administration method. When selecting a glutathione product, reduced glutathione (GSH, the active reduced form) is required — not oxidised glutathione (GSSG). Verify this on the CoA. Additionally, confirm the absence of glutamate impurities and verify purity ≥99% for research-grade material, as lower purity formulations introduce confounding variables into redox experiments. The molecular weight of reduced glutathione is 307.32 g/mol. Lyophilised powder at −20°C with argon or nitrogen headspace (to prevent oxidation during storage) is the gold standard format; glutathione in solution oxidises rapidly and pre-mixed liquid products are inappropriate for serious research use. Reconstitute immediately before use in deoxygenated sterile water or saline to minimise oxidation. In preclinical models, IV or IP doses of 50–200 mg/kg have been used in acute injury and ischaemia-reperfusion protocols. For chronic studies examining systemic redox effects, lower doses (10–50 mg/kg) administered 3–5 times weekly are more appropriate. Researchers should measure oxidative stress biomarkers (GSH:GSSG ratio, 8-OHdG, MDA, TBARS, or F2-isoprostanes) at baseline and at study endpoint to validate biological activity of the intervention. Glutathione works well as an adjunct to other healing peptides in stacks targeting both structural repair (BPC-157, TB-500) and the oxidative stress component of tissue damage, which is an area where it provides unique and non-redundant value.

The most important comparison for glutathione is against its precursor, N-acetylcysteine (NAC). NAC is orally bioavailable, inexpensive, and well-established as a means of raising intracellular GSH by providing cysteine — the rate-limiting substrate for GSH synthesis. In many research contexts, NAC is a practical and cost-effective alternative to direct glutathione supplementation for raising tissue GSH levels. However, direct glutathione administration is preferable when rapid repletion is required (acute injury, ischaemia-reperfusion), when the GSH molecule itself (rather than precursor availability) is the experimental variable of interest, or when systemic delivery via IV is the most practical route. Researchers should consider whether the question is "what does more GSH do?" (direct supplementation) or "can the cell make more GSH given precursors?" (NAC), as these answer different questions. Compared to GHK-Cu as an antioxidant strategy, glutathione is more direct and faster-acting, while GHK-Cu is superior for long-term upregulation of endogenous antioxidant gene expression via Nrf2. A combination of direct GSH supplementation for acute oxidative burden and GHK-Cu for sustained Nrf2-driven antioxidant capacity represents a logical and mechanistically non-redundant approach. Against purely synthetic antioxidants like vitamin C or alpha-lipoic acid, reduced glutathione is superior because it is the primary intracellular antioxidant — vitamins C and E, and alpha-lipoic acid, all ultimately feed electrons back into the glutathione redox cycle, making GSH the downstream effector that their antioxidant activity depends upon. For any research protocol where oxidative stress is a significant component of the pathology being studied, glutathione belongs in the experimental design.